In the present study, we evaluated the anticancer efficacy of a new dual NFAT1-MDM2 inhibitor InuA and examined the possible molecular mechanisms for its activities in preclinical models of human breast cancer in vitro and in vivo. This evidence concerns the gene MDM2 and breast carcinoma.